Updates on Phase 1b TRIMM-2 Study Results of Teclistamab + Daratumumab Presented at EHA 2022

Dr. Paula Rodríguez-Otero (University of Navarra—Pamplona, Spain) discusses updated Phase 1b TRIMM-2 results of Teclistamab Plus Dara in relapsed/refractory multiple myeloma (RRMM) patients. #EHA2022

Abstract Title:
Teclistamab in Combination with Daratumumab, a Novel, Immunotherapy-based Approach for the Treatment of Relapsed/Refractory Multiple Myeloma: Updated Phase 1b Results

What is the purpose of this trial?
Teclistamab (JNJ-64007957) is a B-cell maturation antigen (BCMA) × CD3 T-cell redirecting bispecific antibody currently under investigation in patients with relapsed/refractory multiple myeloma (RRMM). Daratumumab (Dara) is a CD38-targeting monoclonal antibody with direct on-tumor and immunomodulatory mechanisms of action. The preliminary results from the phase 1b multicohort TRIMM-2 study showed tolerable safety with no overlapping toxicities, and encouraging efficacy, supporting the combination of teclistamab with daratumumab for the treatment of RRMM.

Updated results from the TRIMM-2 study with additional patients and longer follow-up are reported here.

Conclusion:
Teclistamab, in combination with daratumumab, is a novel immunotherapy approach that may yield improved clinical efficacy in heavily pretreated patients with RRMM.

Doctor Bio:

Dr. Paula Rodríguez-Otero MD, PhD, is a Specialist in Hematology and Hemotherapy; Medical Coordinator of the Central Unit for Clinical Trials at CIMA Universidad de Navarra and Clinica Universidad de Navarra in Pamplona, Spain.

_______________
Improving Lives | Finding the Cure

In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly.

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.

Find us online:

Category
Nonprofits & Activism
License
Standard YouTube License

In most cases, captions are autogenerated by YouTube.